This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (25)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • HIV/AIDS  • Substance Abuse/ Alcoholism  • Immunology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Esteban Ribera, MD; José M. Miró, MD; Emilia Cortés, MD; Ana Cruceta, MD; Jordi Merce, MD; Francesc Marco, MD; Ana Planes, MD; Joan Carles Paré, MD; Asunción Moreno, MD; Imma Ocaña, MD; José M. Gatell, MD; Albert Pahissa, MD

Arch Intern Med. 1998;158:2043-2050.

Background  Immunosuppression caused by human immunodeficiency virus 1 (HIV) infection appears to modify the clinical characteristics and to increase the severity of several bacterial infections. The impact of HIV infection and the degree of immunosuppression on the clinical characteristics and outcome of infective endocarditis (IE) in intravenous (IV) drug users has not been well characterized.

Methods  Prospective cohort study among 292 consecutive IV drug users with IE diagnosed in 2 academic institutional hospitals in Barcelona, Spain, from January 1, 1984, to October 31, 1995. Serostatus of HIV infection was documented in 283 patients. We measured demographics, clinical and biological data, cause, echocardiographic findings, HIV serostatus and classification, CD4 cell count, complications, and mortality.

Results  Among the 283 episodes of IE, 216 (76.3%) were in HIV-infected patients and 67 (23.7%) in non–HIV-infected patients. Rate of IE per 1000 admissions ranged from 0.17 to 0.82 per year, peaking in 1989. Characteristics of IE independently associated with HIV infection were right-side involvement (odds ratio [OR], 7.6; 95% confidence interval [CI], 3.5-16.7), a micro-organism different from viridans streptococci (OR, 2.5; 95% CI, 1.1-5.9), duration of drug abuse longer than 5 years (OR, 5.0; 95% CI, 2.4-10.3), and white blood cell count of no more than 10x10⁹/L (OR, 2.2; 95% CI, 1.1-4.2). There were no significant differences in mortality due to IE according to HIV serostatus. Among the 216 patients with HIV infection, the variables independently associated with worse outcome were CD4 cell count lower than 0.200x10⁹/L and left-sided or mixed IE.

Conclusions  Although there is a difference in clinical presentation in IE in IV drug users, outcome was similar according to their HIV status. However, among HIV-infected patients, severe immunosuppression and mixed or left-side valvular involvement were strong risk factors for mortality.

From the Infectious Diseases Service (Drs Ribera, Cortés, Ocaña, and Pahissa), Cardiology Service (Dr Merce), and Microbiology and Parasitology Service (Dr Planes), Hospital Vall d'Hebron, Universidad Autónoma de Barcelona, and the Infectious Diseases Service (Drs Miró, Cruceta, Moreno, and Gatell), Microbiology and Parasitology Service (Dr Marco), and Cardiology Service (Dr Paré), Hospital Clínic i Provincial, Universidad de Barcelona, Barcelona, Spain.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC)
Endorsed by the European Society of Clinical Micro et al.
Eur Heart J 2009;30:2369-2413.
FULL TEXT  

Clinical Presentation, Etiology, and Outcome of Infective Endocarditis in the 21st Century: The International Collaboration on Endocarditis-Prospective Cohort Study
Murdoch et al.
Arch Intern Med 2009;169:463-473.
ABSTRACT | FULL TEXT  

Epidemiology and antibiotic treatment of infective endocarditis: an update.
Hoen
Heart 2006;92:1694-1700.
FULL TEXT  

Long-term results after cardiac surgery in patients infected with the human immunodeficiency virus type-1 (HIV-1)
Mestres et al.
Eur. J. Cardiothorac. Surg. 2003;23:1007-1016.
ABSTRACT | FULL TEXT  

Injection drug use and right sided endocarditis
Moss and Munt
Heart 2003;89:577-581.
FULL TEXT  

Infective endocarditis in the Western Cape Province of South Africa: a three-year prospective study
Koegelenberg et al.
QJM 2003;96:217-225.
ABSTRACT | FULL TEXT  

Infective Endocarditis in Adults
Mylonakis and Calderwood
NEJM 2001;345:1318-1330.
FULL TEXT  

Reappraisal of the aetiology and prognostic factors of severe acute respiratory failure in HIV patients
Alves et al.
Eur Respir J 2001;17:87-93.
ABSTRACT | FULL TEXT  

VALVE DISEASE: Worldwide perspective of valve disease
Soler-Soler and Galve
Heart 2000;83:721-725.
FULL TEXT  

Endocarditis and HIV
AIDS Clin Care 1998;1998:4-4.
FULL TEXT